Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Travera Inc
Seagen Inc.
National Institutes of Health Clinical Center (CC)
UNC Lineberger Comprehensive Cancer Center
AstraZeneca
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb
Filamon LTD
Hoffmann-La Roche
Psyence Australia Pty Ltd
ViroMissile, Inc.
Erasca, Inc.
Dana-Farber Cancer Institute
Arvinas Inc.
Essen Biotech
Azienda Ospedaliero-Universitaria di Parma
Icahn School of Medicine at Mount Sinai
St. Jude Children's Research Hospital
MacroGenics
City of Hope Medical Center
xCures
Daiichi Sankyo
University of Nebraska
Memorial Sloan Kettering Cancer Center
Natera, Inc.
Second Life Therapeutics
City of Hope Medical Center
Mayo Clinic
Degron Therapeutics Co.
Cancer Research UK
Abramson Cancer Center at Penn Medicine
M.D. Anderson Cancer Center
Revolution Medicines, Inc.
Tempus AI
Massive Bio, Inc.
UNC Lineberger Comprehensive Cancer Center
Actym Therapeutics, Inc.
Institut Bergonié
Day One Biopharmaceuticals, Inc.
Ikena Oncology
National Institutes of Health Clinical Center (CC)
UNC Lineberger Comprehensive Cancer Center
Memgen, Inc.
Washington University School of Medicine
Palleon Pharmaceuticals, Inc.
Sensei Biotherapeutics, Inc.
Day One Biopharmaceuticals, Inc.
Cancer Research UK
Delfi Diagnostics Inc.